Esketamine Spravato Treatment

Meeting the Needs of Patients with Treatment-Resistant Depression at UTHealth HCPC

EsketamineSpravatoTreatment

Our hospital is now offering intranasal esketamine (Spravato) for those depression patients who have not got better with more than two antidepressant trials. Spravato is a self-administered nasal spray in a medical office setting. Your first visit will be a consultation to discuss the details including other treatment options and the risks of misuse, abuse, sedation and dissociation of Spravato with a healthcare provider. If your provider confirms that Spravato is right for you, then you will enrolled in Private Risk Evaluation Mitigation Strategy (REMS) Program. You may start treatment on your next visit. After you take Spravato, a healthcare provider will monitor you for at least two hours during the observation period for possible side effects during your visits. Spravato is taken twice a week for the first four weeks, and then once a week for a month. After the initial treatment, it is usually taken either once a week or once every two weeks. Spravato is brought bySalih Selek, M.D., who oversees the hospital’s Refractory Mood Disorders Program.

UTHealth HCPC is committed to providing comprehensive care in a comfortable and compassionate setting, including acute and maintenance treatment. If you are interested in referring a patient or have any questions, please do not hesitate tocall the ECT Clinic at 713-741-3930 or 713-741-5915.